ClinicalTrials.gg
CompletedNCT00157716Updated Oct 31, 2006

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

A Phase 2 interventional study of (MC-1) Pyridoxal-5'-phosphate in Coronary Artery Bypass Graft Surgery, Myocardial Ischemia and Reperfusion Injury, sponsored by Medicure. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-10-31.

Sponsored by Medicure · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies in Myocardial Ischemia with a site in United States — 23 open to participants now, 26 under way, none of them phase 3. Myocardial Ischemia · United States.

Enrollment
36th of 150
900 · median 87
Started
2004
with 9 others
Phase 2
27 of 218
2 open now
Registered
23rd of 218
by date

Among the 218 studies in Myocardial Ischemia with a site in United States, this one is the 36th largest by enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2004, is one of 27 in phase 2, and was the 23rd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

23 of the 218 studies in Myocardial Ischemia with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Myocardial Ischemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery

Read the detailed description

Coronary artery bypass grafting (CABG) effectively relieves angina, results in longer survival, and a better quality of life in specific subgroups of patients with obstructive coronary artery disease. Due to the high incidence of coronary artery disease worldwide, as well as the effectiveness of the surgical procedure, CABG surgery makes up one of the top ten most frequently performed procedures in North America and Europe. In the United States it is estimated that over 700,000 CABG procedures are performed per year.

Despite the benefits of CABG surgery, patients undergoing these procedures may also suffer serious adverse outcomes including operative mortality, myocardial infarction, unstable angina, ventricular failure, life-threatening arrhythmia, renal insufficiency, and stroke.

Some of the proposed causes of cardiovascular morbidity and mortality after CABG include perioperative ischemia, inadequate myocardial protection and reperfusion injury. The impact of these serious complications is significant. Incidence rates of death and MI following CABG surgery range from 5% to 12% depending on risk status. Results from large clinical trials have recently demonstrated the importance of neurologic deficits as a problematic outcome of CABG. These deficits include memory impairment, psychomotor, visuospatial, attention and language abilities as measured by neuropsychological testing as well as sensori-motor abnormalities associated with stroke.

MC-1 is a naturally occurring small molecule. Evidence from pre-clinical and clinical studies suggests that MC-1 protects the heart from ischemic damage and ischemia-reperfusion injury. This trial will assess the effects of MC-1 compared to placebo on cardiovascular and neurological events following CABG surgery.

03

Conditions studied

  • Coronary Artery Bypass Graft Surgery
  • Myocardial Ischemia
  • Reperfusion Injury
  • Myocardial Revascularization

Keywords

  • Coronary
  • surgery
  • ischemia
  • reperfusion injury
  • cardiac
  • heart
  • neurological
  • cardiopulmonary bypass
  • cardioprotection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must be scheduled to undergo CABG surgery (during routine scheduling times) planned to use cardiopulmonary bypass

Patients must be considered at high risk for subsequent neurological or myocardial complications defined as meeting 2 or more of the following:

  • Age >65
  • Current smoker
  • History of diabetes mellitus requiring treatment other than diet
  • Evidence of left ventricular dysfunction or congestive heart failure assessed by: (EF) \<45%, left ventricular end diastolic pressure (LVEDP) or pulmonary wedge pressure greater than or equal to 20 mm Hg, pulmonary edema by chest X-ray, cardiothoracic ratio >50% on chest X-ray
  • History of a previous non-disabling stroke, , or carotid endarterectomy
  • Urgent CABG intervention defined as the need to stay in the hospital (although patient may be operated on within a normal scheduling routine
  • History of a myocardial infarction that occurred more than 48 hours but less than 6 weeks prior to CABG surgery
  • Prior peripheral artery surgery or angioplasty
  • Moderate renal dysfunction defined by creatinine ≥ 133 micromol/L (1.5 mg/dL), but \< 250 micromol/L (2.8 mg/dL)
  • Presence of at least one asymptomatic carotid artery stenosis (≥50%) either in one or two carotid arteries

Exclusion criteria

Exclusion Criteria:

  • Planned associated valve surgery or concurrent carotid endarterectomy
  • Planned aortic dissection repair or aortic root reconstruction
  • Screening visit occurring less than 4 hours before scheduled CABG surgery
  • score less than 24 at the screening visit
  • Current cardiogenic shock, acute left ventricular rupture, ventricular septal rupture, or papillary muscle rupture
  • Uncontrolled diabetes defined as fasting serum blood glucose value equal to or greater than 24 mmol/L (432 mg/dL) at the time of screening (if fasting serum blood glucose not obtained at screening, values obtained within 30 days prior to screening visit may be used)
  • Myocardial infarction occurring \<48 hours prior to planned CABG surgery
  • Severe renal dysfunction defined as a serum creatinine value ≥ 250 micromol/L (2.8 mg/dL) or nephritic syndrome at screening (or obtained within 30 days prior to screening visit)
  • History of liver cirrhosis, chronic active hepatitis, or severe liver dysfunction , or liver transaminase ≥3 times at screening (or obtained within 30 days prior to screening visit)
  • History of during last 5 years except for basal cell carcinoma
  • Planned surgery for atrial fibrillation
  • Pregnancy or potential for pregnancy
  • Any medical or psychiatric condition which in the opinion of the investigator makes the patient an unsuitable candidate for the study
  • History of alcohol or drug abuse within the past year
  • Participation in any other investigation drug or device study within 30 days of randomization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
900 participants
06

What researchers measure

Primary outcomes

  1. Combined incidence of cardiovascular death, nonfatal myocardial infarction and nonfatal cerebral infarction on days up to and including post-operative day 30.

Secondary outcomes

  1. Combined incidence of cardiovascular death, nonfatal myocardial infarction and nonfatal cerebral infarction up to and including post-operative day (POD) 90

  2. Incidence of cardiovascular death up to and including POD 4, POD 30, POD 90

  3. Incidence of nonfatal myocardial infarction up to and including POD 4, POD 30, POD 90

  4. Incidence of all cause morality up to and including POD 4, POD 30, POD 90

  5. Global disability as measured by the Modified Rankin scale at POD 30 and POD 90

  6. MMSE score at POD 30 and POD 90

  7. Among patients with a confirmed cerebral infarction, severity of stroke as measured by the National Institutes of Health Stroke Scale (NIHSS) at the time of stroke diagnosis and at subsequent study visits up to and including POD 90

  8. Psychometric testing results as measured by a short battery of tests at POD 4, POD 30 and POD 90 on a subset of approximately 150 volunteers per treatment arm

  9. CK-MB AUC (0-24 hours)

07

Study locations

2 sites
  • Duke University Medical Center
    Durham, North Carolina 27710-7510, United States
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Apr 2004
Completion
Oct 2005
Last update
Oct 31, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Oct 31, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00157716
Lead sponsor
Medicure
First posted
Sep 12, 2005
Start date
Apr 2004
Completion
Oct 2005
Last update
Oct 31, 2006

Study contacts

Jean-Claude Tardif, MD, FRCPC, FACC
principal investigator · Montreal Heart Institute Research Centre
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyridoxal Phosphate

Start the discussion